Rosenblatt J., Rosenberg R., Anand A. (2024). Using Longitudinal Claims Data to More Accurately Predict Response Uptake Curves in Rare & Ultra Rare Disease. [Theater Presentation] PMSA 2024. May 5-8. Denver, USA.

*NEW* Sicilia M., van der Pluijm W. (2026) Machine Learning to Differentiate Congestive Heart Failure Onset Among High-Risk Patients Identified by the Framingham Risk Score ISPOR 2026. May 17-20. Philadelphia, USA.

*NEW* Panthari A., Sicilia M., van der Pluijm W. (2026) Declining Baseline HbA1c at GLP-1 Receptor Agonist Initiation in U.S. Adults with Type 2 Diabetes, 2015-2024. ISPOR 2026. May 17-20. Philadelphia, USA.

*NEW* Sicilia M., van der Pluijm W. (2026) Real-World Concordance With the Framingham Stroke Risk Model in Atrial Fibrillation and Identification of Additional Significant Features. ISPOR 2026. May 17-20. Philadelphia, USA.

*NEW* van der Pluijm W., Neilson D., Anand A. (2026) Association Between GLP-1 Receptor Agonist Initiation and Alcohol Use Disorder and Alcohol-Related Medical Conditions in a U.S. Administrative Claims Database. ISPOR 2026. May 17-20. Philadelphia, USA.

*NEW* Panthari A., Sicilia M., van der Pluijm W. (2026) Observed Cardiovascular Disease Prevalence Among Obese and Type 2 Diabetes Patients With and Without GLP-1 Treatment. ISPOR 2026. May 17-20. Philadelphia, USA.

*NEW* van der Pluijm W., Sicilia M., Anand A. (2026) Trends in Preeclampsia Prevalence and Comorbidity Burden Among Pregnant Women Using U.S. Administrative Claims Data. ISPOR 2026. May 17-20. Philadelphia, USA.

*NEW* Sicilia M. (2026) Observed Real-World Diagnosis and Specialist Visit Patterns in Newly Diagnosed and Relapsing MS Patients. ISPOR 2026. May 17-20. Philadelphia, USA.

*NEW* Chambers L., Ramu A., Aushev V., Rojahn S., Antonopoulos A., Scalise C., Salmasi F., Liu M., ElNaggar A., Arend A. (2026) Genomic and Ancestry-Associated Determinants of Survival in Gynecologic Cancers. American Association for Cancer Research (AACR) 2026. April 17-22. San Diego, USA.

*NEW* Lyons G., Vlasnik J., Jastrab A., Abramson A., Sullivan B., Anand A., Sicilia M., Panthari A., Peroutka C. (2026) Genetic characterization and clinical manifestations in adults with hypophosphatasia in the United States. Annual Clinical Genetics Meeting (ACGM) 2026. March 10-14. Baltimore, USA.

Hadac J., Anand A., Jones J., Neilson D., van der Pluijm W., Wu A., Fok L. (2025) Understanding Patient Experience in the Management and Prioritization of MASH and Combordities: Results from a Claims Analysis and Qualitative Patient Interviews. World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) 2025. December 3-6. Los Angeles, USA.

Meade J., Lyons G., Anand A., Sicilia M., van der Pluijm W., Bowling A., Guikema B., Dettling T. (2025) Effect of Selumetinib Treatment on Long-Term Pain Medication Utilization in Pediatric Patients: A Retrospective Study of a US Claims Database. Society for Neuro-Oncology Annual Meeting (SNO) 2025. November 19-23. Honolulu, USA.

Ragole T., Blackowicz M., Weiskopf E., Anand A., Sicilia M. (2025). Corticosteroid Toxicity and Related Healthcare Resource Utilization in Patients with Myasthenia Gravis in the USA. [Poster Presentation] American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting 2025. October 29-November 1. San Francisco, USA.

Sicilia M., van der Pluijm W. (2025). Concomitant Usage of Contraindicated Medications in Patients with Atrial Fibrillation: A Comparison of RWD Sources in the US. ISPOR 2025. May 13-16. Montreal, QC, Canada.

van der Pluijm W., Sicilia M. (2025). Trends in GLP-1 Utilization for Diabetes and Obesity in the US: A Retrospective Analysis (2017-2023). ISPOR 2025. May 13-16. Montreal, QC, Canada.

van der Pluijm W., Sicilia M. (2025). Baseline BMI and HbA1c Trends in US Diabetic Patients Initiating GLP-1 Therapy: A Retrospective Cohort Study. ISPOR 2025. May 13-16. Montreal, QC, Canada.

Simeone J., Mevius A., van der Pluijm W., Sicilia M. (2025). Early Breast Cancer in the US and Germany: A Comparison of Real-World Screening and Treatment. ISPOR 2025. May 13-16. Montreal, QC, Canada.

Lian L., Johnston C., Seo M., Kitrinos K., Gaggar A., Deer, J. (2025) Estimating Genital Herpes Prevalence and Treatment Patterns Among US Healthcare-Engaged Individuals: Insights from Claims Data. [Poster Presentation] Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025. April 11-15. Vienna, Austria.

Ragole T., Blackowicz M., Weiskopf E., Anand A., Sicilia M., Wolfe G. (2025). Longitudinal Associations of Corticosteroid Dose with Corticosteroid Toxicity in Patients with Myasthenia Gravis in the USA. MDA 2025. March 16-19. Dallas, USA.

Kuranz S. (2024). Emergency Room Utilization Among Multiple Sclerosis Patients Treated with Disease-Modifying Therapy in a Real-World Hybrid Claims Database. ISPOR 2024. May 5-8. Atlanta, USA.

Kuranz S., Westall T. (2024). Patterns of Treatment Initiation By Sarcoidosis Type in a Real-World Hybrid Claims Database. ISPOR 2024. May 5-8. Atlanta, USA.

Kuranz S. (2023). Progression to ESRD Among White, Black and Hispanic Diabetic Kidney Disease Patients: Real-World Evidence from Multiple Linked Claims Databases. [Abstract]. ICPE Annual Conference 2023. August 23-27. Halifax, Canada.

Zylla D., Knowlton G., Gilmore G., Pawloski PA, Salz T. Kulkarni AA, Cowger J., Kuranz S. (2023). Association of Cannabis Use with Real-World Time to Treatment Discontinuation in Advanced Cancer Patients Initiating Immune Checkpoint Inhibition. [Abstract]. ASCO Annual Meeting 2023. June 2-6. Chicago, USA.

Kuranz S., Neilson D. (2023). Real World Evidence on the Use of ECMO in Hospitalized COVID-19 Patients: Results From a Linked Closed and Open Claims Database in the US. ISPOR 2023. May 7-10. Boston, USA.

Kuranz S. (2023). Adherence and Persistence with SGLT-2 Inhibitors among White and Black Diabetic Kidney Disease Patients: Real-World Evidence From a Large US Claims Database. ISPOR 2023. May 7-10. Boston, USA.

Kuranz S., Neilson D., van der Pluijm W. (2023). Estimating the Cost of End-of-Life Care Among US Adults: Real-World Evidence Using a Case-Crossover Study Design. ISPOR 2023. May 7-10. Boston, USA.

Kuranz S., Anand A., van der Pluijm W. (2023). Real-world Evidence on the Association Between the Use of Cannabis and Healthcare Resource Utilization Among Patients With Chronic Post-Traumatic Stress Disorder. ISPOR 2023. May 7-10. Boston, USA.

Kuranz S., van der Pluijm W. (2022). The Cost of Care Among Infantile and Child Spinal Muscular Atrophy Patients: RWE From a Large Claims Database. ISPOR Europe 2022. November 6-9. Vienna, Austria.

Fishman J., Hubbert A., van der Pluijm W., Zhang C., Sun An Y. (2022). Epidemiological Estimate of the Prevalence of the Coded Nonalcoholic Steatohepatitis (NASH) Population in the US Using an Administrative Claims Dataset. ISPOR Europe 2022. November 6-9. Vienna, Austria.

Other Media

*NEW* Hadac J., Anand A., Jones J., van der Pluijm W., Wu A., Fok L. (2026) Understanding Patient Experience in the Management and Prioritization of MASH and Comorbidities: Results from a Claims Analysis and Qualitative Patient Interviews. Metabolism Journal. April 2026.

Sicilia M. (2025). Choosing the Right Data for the Right Insight: Comparing US Real-World Data Sources in the Context of Atrial Fibrillation. The Evidence Base.

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress. (2025). 

Sicilia M. (2024). Beyond Access: How Wealth and Race Shape GLP-1 Treatment Outcomes in Diabetes and Weight Loss. 

Kuranz, S. (2023). Real-world Evidence Generation From Hybrid Claims Data: An Interview With Seth Kuranz, Forian Inc. The Evidence Base.

Rhyee, C. (Host). (2023, August 16). Understanding and Leveraging Healthcare Data with Paul Reuscher. [Audio podcast episode]. In TD Cowen Insights Podcase: FutureHealth Podcast Series. 

Kuranz, S. (2023). Introduction to CHRONOS: Forian’s Hybrid Real-World Data Ecosystem.